. Acadpharm and . Cholestyramine, , vol.15, 2016.

E. Ajufo and D. J. Rader, Recent advances in the pharmacological management of hypercholesterolaemia, The Lancet, vol.4, issue.5, pp.436-446, 2016.

. Ameli, Le risque cardiovasculaire et ses facteurs

A. L. Amundsen, L. Ose, M. S. Nenseter, and F. Y. Ntanios, Plant Sterol ester-enriched spread lowers plasma total and LDL-cholesterol in children with familial hypercholesterolemia, The American Journal of Clinical Nutrition, vol.76, issue.2, pp.338-344, 2002.

T. J. Anderson, J. Grégoire, R. A. Hegele, P. Couture, G. B. Mancini et al., 2012 update of the Canadian Cardiovascular Society Guidelines for the Diagnosis ant Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, Canadian Journal of Cardiology, vol.29, issue.2, pp.151-167, 2013.

. Anhet, Quels examens peuvent être prescrits pour dépister et suivre l'hypercholestérolémie familiale ?

A. and A. , Agence nationale de sécurité sanitaire de l'alimentation de l'environnement et du travail relatif à « Evaluation du risque et du bénéfice liés à la consommation de produits alimentaires enrichis en phytostérols ou en phytostanols, 2014.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé « Compléments alimentaires à base de levure de riz rouge : mises en garde de l'ANSMPoint d'information, 2018.

, ANSM Recommandations pour le bon usage des autotests vendus en pharmacie-Point d'information publié le 8 février, 2018.

M. Arca, Atherosclerosis, Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH) : The promises of PCSK9 inhibitors, Atherosclerosis, vol.256, pp.134-145, 2017.

A. Astrup, J. Dyerberg, P. Elwood, K. Hermansen, F. B. Hu et al., The role of reducing intakes of saturated fat in the prevention of cardiovascular disease : where does the evidence stand in 2010 ?, Am J Clin Nutr, vol.93, issue.4, pp.684-688, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00730164

D. Attias and B. Besse, Lellouche N. Cardiologie Vasculaire Vernazobres-Grego, 2013.

C. Ballantyne, Clinical Lipidology : A Companion to Braunwald's Heart Disease. 2ème édition, 2014.

B. Bates, L. Bickley, . Jl, and G. Durand, Guide de l'examen clinique : nouvelle édition 2014. Arnette, 2014.

. Lavoisier, , 2011.

L. Becquemont, Interactions médicamenteuses et hypolipémiants, Thérapie, vol.58, issue.1, pp.85-90, 2003.

S. Béliard, F. Bonnet, B. Bouhanick, E. Bruckert, B. Cariou et al., Consensus statement on the management of dyslipidaemias in adults, Diabetes Metab, vol.78, issue.1, pp.43-53, 2016.

S. Béliard, V. Carreau, A. Carrié, P. Giral, E. Duchêne et al., Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia : can we do better ? Analysis of results obtained during the past two decades in 1669 French subjects, Atherosclerosis, vol.234, issue.1, pp.136-141, 2014.

M. Benn, G. F. Watts, A. Tybjaerg-hansen, . Nordestgaard, and . Bg, Mutations Causative of Familial Hypercholesterolaemia : Screening of 98 098 Individuals from the Copenhagen General Population Study Estimated a Prevalence of 1 in 217, European Heart Journal, vol.37, issue.17, pp.1384-1394, 2016.

J. Blacher and D. Agnoletti, Échelles de risque cardiovasculaire : Cardiovascular risk scales, Médecine des Maladies Métaboliques, vol.5, issue.3, 2011.

D. J. Blom, T. Hata, M. Bolognese, M. J. Lillestol, P. D. Toth et al., A 52 week placebo controlled trial of evolocumab in hyperlipidemia, The New England Journal of Medicine, vol.370, issue.19, pp.1809-1819, 2014.

R. H. Boger, Drug interactions of the statins and consequences for drug selection, Int J Clin Pharmacol Ther, vol.39, issue.9, pp.369-382, 2001.

J. P. Bounhoure and A. Vacheron, Prévention cardiovasculaire et principaux facteurs de risque, 2017.

J. L. Bourre and . Cholestérol, , 1997.

E. Bruckert, J. Chapman, J. Ferrières, and M. Krempf, Livre blanc : approche diététique de l'hypercholestérolémie, 2015.

G. Camus and ». Qu'appelle-t'on-«-bon, , 2018.

C. P. Cannon, IMPROVE-IT Trial : A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes, 2014.

, American Heart Association, vol.456, issue.5, pp.826-832

A. L. Catapano, I. Graham, D. Backer, G. Wiklund, O. Chapman et al., , 2016.

, ESC/EAS guidelines for the management of dyslipidaemias, Eur Heart J, vol.70, issue.2

C. Caulin, Vidal Recos Recommandations en pratique, Vidal, 6ème édition, 2015.

H. Cederberg, A. Stancakova, N. Yaluri, S. Modi, J. Kuusisto et al., Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion : a 6 year follow-up study of the METSIM cohort, Diabetologia, vol.58, issue.5, pp.1109-1117, 2015.

, Centre National Hospitalier d'Information sur le Médicament (CNHIM), 2005.

P. H. Chong, J. D. Seeger, and C. Franklin, Clinically relevance differences between the statins : implications for therapeutic selection, Am J Med, vol.111, issue.5, pp.390-400, 2001.

F. Civeira, E. Ros, E. Jarauta, N. Plana, D. Zambon et al., Comparison of Genetic versus Clinical Diagnosis in Familial Hypercholesterolemia, The American Journal of Cardiology, vol.102, issue.9, pp.1187-1193, 2009.

M. Coker, S. K. Ucar, D. G. Simsek, S. Darcan, M. Bak et al., Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia, 2009.

, Ther Apher Dial, vol.13, issue.2, pp.121-128

, Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality, JAMA : The Journal of the American Medical Association, vol.302, issue.4, pp.412-423, 2009.

V. Collectif and . Le-dictionnaire, , 2018.

R. Conroy, K. Pyörälä, A. Fitzgerald, S. Sans, A. Menotti et al., Estimation of Ten-Year Risk of Fatal Cardiovascular Disease in Europe : The SCORE Project, European Heart Journal, vol.24, issue.11, pp.987-1009, 2003.

, Conseil scientifique des concours de l'internat en pharmacie. Valeurs biologiques usuelles, 2009.

A. Couriol and K. Chevalier, Synthèse couteuse en énergie, 2018.

M. Cuchel, E. Bruckert, H. N. Ginsberg, F. J. Raal, R. D. Santos et al., Homozygous Familial Hypercholesterolaemia : New Insights and Guidance for Clinicians to Improve Detection and Clinical Management. A Position Paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, European Heart Journal, vol.35, issue.32, pp.2146-2157, 2014.

J. Dallongeville, N. Marecaux, and P. Amouvel, Acides gras oméga-3 et risque cardiovasculaire, OCL Journal, vol.17, issue.4, pp.232-235, 2010.

D. Jong, A. Plat, J. Bast, A. Godschalk, R. W. Basu et al., Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment, Eur J Clin Nutr, vol.62, issue.2, pp.263-273, 2008.

E. M. Degoma, Z. S. Ahmad, E. C. O'brien, I. Kindt, P. Shrader et al., Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States : data from the CASCADE-FH Registry, Circ Cardiovasc Genet, vol.9, issue.3, pp.240-249, 2016.

O. S. Descamps, Les inhibiteurs de PCSK9 : une nouvelle classe d'hypolipémiants, Louvain Med, vol.135, issue.5, pp.291-297, 2016.

N. R. Desai, P. Kohli, R. P. Giugliano, M. L. O'donoghue, R. Somaratne et al., , 2013.

, AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy : an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy

, Thrombolysis in Myocardial Infarction (TIMI) 57 trial, Circulation, vol.128, issue.9, pp.969-969

. Diabete and . Colesterolo, , 2018.

, Autotests vendus en pharmacie : comment les utiliser ?, 2018.

, EBBINGHAUS : Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects. ClinicalTrials.gov Identifier : NCT02207634

E. Biologie, Autotests : pertinence médicale et limites, 2018.

, Praluent : EPAR Product Information, 2018.

, Repatha : EPAR Product Information

P. V. Ennezat and . Cardiologie, Med-Line Editions, 2007.

R. Estruch, M. A. Martínez-gonzález, D. Corella, J. Salas-salvadó, M. Fitó et al., Effect of a high-fat Mediterranean diet on bodyweight and waist circumference : a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial, The Lancet, vol.4, issue.8, pp.666-676, 2016.

R. Estruch, E. Ros, J. Salas-salvadó, M. I. Covas, D. Corella et al., Primary Prevention of Cardiovascular Disease with a Mediterranean Diet, New England Journal of Medicine, vol.369, issue.7, pp.676-677, 2013.

M. Farnier, Comment je fais le diagnostic d'une hypercholestérolémie familiale ? Cordiam, 6, 2015.

M. Farnier, E. Bruckert, C. Boileau, and M. Krempf, Diagnostic et traitement des HF chez l'adulte : recommandations de la Nouvelle société française d'athérosclérose (NSFA), 2013.

K. Feltgen, . Poulletier-de-la-salle, . La-découverte-du-cholestérol, and . Chu-de-rouen, , 2016.

S. D. Ferranti, A. M. Rodday, M. M. Mendelson, J. B. Wong, L. K. Leslie et al., Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES), Circulation, issue.18, pp.395-396, 2016.

J. Ferrières, Les recommandations de 2016 de la Société européenne de cardiologie sur la prise en charge des dyslipidémies, La Presse Médicale, vol.46, issue.7-8, pp.688-696, 2017.

, Fondation Coeur et artères, Le sel en petite quantité, 2018.

C. Gagné, D. Gaudet, and E. Bruckert, Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia, Circulation, issue.21, pp.2469-2475, 2002.

M. Garcia-calvo, J. M. Lisnock, H. Bull, B. Hawes, D. Burnett et al., The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), pp.8132-8137, 2005.

S. S. Gidding, M. A. Champagne, D. Ferranti, S. D. Defesche, J. Ito et al., The agenda for familial hypercholesterolemia. A scientific statement from the American heart association, Circulation, vol.132, issue.22, pp.2167-2192, 2015.

P. Giral, Athérome : anatomie pathologique, physiopathologie, épidémiologie et facteurs de risque, prévention, Rev Prat, vol.48, issue.1, pp.99-106, 1998.

J. P. Girardet, Hypercholestérolémie familiale : diagnostic, prise en charge, dépistage, JIM, vol.42, issue.6, pp.930-950, 2016.

J. P. Girardet, Indications des statines chez l'enfant hypercholestérolémique, Arch Pediatr, vol.22, issue.8, pp.900-903, 2015.

J. P. Girardet, G. Luc, D. Rieu, E. Bruckert, D. Darmaun et al., Prise en charge des hypercholestérolémies de l'enfant : recommandations du Comité de nutrition de la Société française de pédiatrie et de la Nouvelle société française d'athérosclérose, Arch Pediatr, vol.18, issue.2, pp.217-229, 2011.

A. C. Goldberg, P. N. Hopkins, P. P. Toth, C. M. Ballantyne, D. J. Rader et al., Familial hypercholesterolemia : screening, diagnosis and management of pediatric and adult patients. Clinical guidance from the National Lipid Association Expert Panel on Familial hypercholesterolemia, J Clin Lipidol, vol.5, issue.3, pp.1-8, 2011.

R. Y. Gordon, T. Cooperman, W. Obermeyer, and D. J. Becker, Marked variability of monacolin levels in commercial red yeast rice products : buyer beware, Arch Intern Med, vol.170, issue.19, pp.1722-1727, 2010.

N. Hagiwara, E. Kawada-watanabe, R. Koyanagi, H. Arashi, J. Yamaguchi et al., Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia : the HIJ-PROPER study, a prospective, open-label, randomized trial, Eur Heart J, vol.38, issue.29, pp.2264-2276, 2017.

D. Hammersley and M. Signy, Ezetimibe : an update on its clinical usefulness in specific patient groups, vol.8, pp.4-11, 2017.

B. Hansel and P. Giral, Cholestérol alimentaire et morbi/mortalité cardiovasculaire, Oilseeds & fats Crops and Lipids Journal, vol.50, issue.4, pp.202-208, 2015.

M. Harada-shiba, H. Arai, S. Oikawa, T. Ohta, T. Okada et al., Guidelines for the management of familial hypercholesterolemia, J Atheroscler Thromb, vol.19, issue.12, pp.1043-1060, 2012.

W. S. Harris, D. Mozaffarian, E. Rimm, P. Kris-etherton, L. L. Rudel et al., , 2009.

, Omega-6 fatty acids and risk for cardiovascular disease : a science advisory from the

, American Heart Association Nutrition subcommittee of the Council on Nutrition, Physical Activity, and Metabolism ; Council on Cardiovascular Nursing ; and Council on Epidemiology and Prevention, Circulation, vol.119, issue.6, pp.902-907

, Avis de la Commission de la Transparence du 16 décembre 2015 HAS. Évaluation et prise en charge du risque cardio-vasculaire

, Direction de l'Evaluation Médicale, Economique et de Santé Publique, HAS, 2017.

H. Fiche, , 2017.

H. Fiche, Principales dyslipidémies : stratégies de prise en charge, 2018.

, Rapport d'élaboration de la fiche mémo sur les principales dyslipidémies : stratégies de prise en charge, HAS

F. J. He, J. Li, and G. A. Macgregor, Effect of longer term modest salt reduction on blood pressure : Cochrane systematic review and meta-analysis of randomised trials, BMJ, p.346, 2013.

E. Hebert, Les composés lipidiques en cosmétologie Publié le 4 février 2013

H. Linda and C. , Familial hypercholesterolemia : current treatment opinions and patient selection for low-density lipoprotein apheresis, J Clin Lipidol, vol.4, pp.346-349, 2010.

H. F. Hendriks, J. A. Weststrate, T. Van-vliet, and G. W. Meijer, Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects, Eur J Clin Nutr, vol.53, issue.4, pp.319-327, 1999.

L. Hooper, C. D. Summerbell, R. Thompson, R. Sills, F. G. Roberts et al., Reduced or modified dietary fat for preventing cardiovascular disease, Cochrane Database, vol.134, issue.2, pp.182-183, 2011.

P. Hopkins, P. Toth, C. Ballantyne, and D. Rader, Familial Hypercholesterolemias : Prevalence, Genetics, Diagnosis and Screening Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, Journal of Clinical Lipidology, vol.5, issue.3, pp.9-17, 2011.

L. C. Hudgins, B. R. Gordon, and T. S. Parker, LDL apheresis : an effective and safe treatment for refractory hypercholesterolemia, Cardiovasc Drug Rev, vol.20, issue.4, pp.271-280, 2002.

R. Hussain, S. Yusuf, H. Wayne, M. Giles, B. Janet et al., Impact of Multiple Risk Factor Profiles on Determining Cardiovascular Disease Risk, Preventive Medicine, vol.27, issue.1, pp.1-9, 1998.

L. Jakulj, M. N. Vissers, A. K. Groen, B. A. Hutten, D. Lutjohann et al., Baseline Cholesterol Absorption and the Response to Ezetimibe/Simvastatin Therapy : A Post-Hoc Analysis of the ENHANCE Trial, Journal of Lipid Research, vol.51, issue.4, pp.755-762, 2010.

J. U. Frind, A. Tselmin, S. Kopprasch, S. Poberschin, I. Siegert et al., Comparison of different LDL apheresis methods, Expert Rev Cardiovasc Ther, vol.6, issue.5, pp.629-639, 2008.

M. Juneau, Sel et maladies cardiovasculaires. Observatoire de la prévention, 2017.

P. R. Kamstrup, A. Tybjaerg-hansen, and B. G. Nordestgaard, Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, J Am Coll Cardiol, vol.63, issue.5, pp.470-477, 2014.

J. J. Kastelein, F. Akdim, E. Stroes, A. H. Zwinderman, M. L. Bots et al., Simvastatin with or without ezetimibe in familial hypercholesterolemia, New Engl J Med, vol.359, issue.5, pp.529-530, 2008.

J. J. Kastelein, G. K. Hovingh, G. Langslet, M. T. Baccara-dinet, D. A. Gipe et al., Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab versus placebo in patients with heterozygous familial hypercholesterolemia, J. Clin. Lipidol, vol.37, issue.48, pp.3588-3595, 2017.

M. B. Katan, S. M. Grundy, P. Jones, M. Law, T. Miettinen et al., Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels, Mayo Clin Proc, vol.78, issue.8, pp.965-978, 2003.

D. S. Kazi, A. E. Moran, P. G. Coxson, J. Penko, D. A. Ollendorf et al., Costeffectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease, JAMA, issue.7, pp.743-753, 2016.

S. Kirkiacharian, Guide de chimie médicinale et médicaments, Editions TEC & DOC, 2010.

M. J. Koren, P. Lundgvist, M. Bolognese, J. M. Neutel, M. L. Monsalvo et al., Anti-PCSK9 monotherapy for hypercholesterolemia : the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab, J Am Coll Cardiol, vol.63, issue.23, pp.2531-2540, 2014.

K. Laitinen, E. Isolauri, L. Kaipiainen, H. Gylling, and T. A. Miettinen, Plant stanol ester spreads as components of a balanced diet for pregnant and breast-feeding women : evaluation of clinical safety, Br J Nutr, vol.101, issue.12, pp.1797-1804, 2008.

J. M. Lecerf, Cahier de Nutrition et de Diététique. Lipides et santé, 2007.

J. M. Lecerf, Le cholestérol alimentaire : Effets sur les lipides plasmatiques et sur le risque cardiovasculaire, Bulletin d'informations scientifiques, p.14, 2012.

J. M. Lecerf and J. L. Schlienger, Nutrition prévention et thérapeutique, éditions, 2016.

C. J. Lehmann-, . Lipoprotéines, and B. Et-dyslipidémies, , 2016.

J. Léoni, Physiopathologie de l'athérosclérose Mécanismes et prévention de l'athérothrombose, Th D Pharm, 2001.

Q. Li, Y. Cui, R. Jin, H. Lang, H. Yu et al., Enjoyment of Spicy Flavor Enhances Central Salty-Taste Perception and Reduces Salt Intake and Blood Pressure, Hypertension, vol.70, issue.6, pp.1291-1299, 2017.

J. K. Liao, Beyond lipid lowering : The role of statins in vascular protection, Int J Cardiol, vol.86, issue.1, pp.5-18, 2002.

P. Liebermann, M. Vaubourdolle, L. Grangeot-keros, F. Blanchet, F. Brion et al., Autotest-TROD Rôle du pharmacien d'officine. Académie nationale de Pharmacie, 2017.

K. Liu, M. L. Daviglus, C. M. Loria, L. A. Colangelo, B. Spring et al., Healthy Lifestyle through Young Adulthood and the Presence of Low Cardiovascular Disease Risk Profile in Middle Age : The Coronary Artery Risk Development in (Young) Adults (CARDIA) Study, Circulation, vol.125, issue.8, pp.996-1004, 2012.

M. Lui, R. Garberich, T. Strauss, and T. Davin, Knickelbine, Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia, J. Lipids, p.864317, 2014.

K. Maeda, Y. Noguchi, and T. Fukui, The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles : a meta-analysis, vol.37, pp.283-290, 2003.

K. C. Maki, J. L. Slavin, T. M. Rains, and P. M. Kris-etherton, Limitations of Observational Evidence : Implications for Evidence-Based Dietary Recommendations, Advances in Nutrition, vol.5, issue.1, pp.7-15, 2014.

M. Marduel, A. Carrié, A. Sassolas, M. Devillers, V. Carreau et al., Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France, Human Mutations, vol.31, issue.11, pp.1811-1824, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00573066

Z. Massy, F. Andreelli, M. Andrejak, and B. Lanour, Cholestérol et triglycérides Doin Editions, 2004.

Z. Massy, M. Brazier, E. Housieaux, S. Kamel, and A. Et-wattel, Le cholestérol Groupe Liaisons, 2007.

S. Meyer-rogge, K. Meyer-rogge, . Biochimie-métabolique-de, and . Boeck, , 2012.

W. Meyer-sabellek and H. Brasch, Atherosclerosis, inflammation, leukocyte function and the effect of statins, J Hypertens, vol.24, issue.12, pp.2349-2351, 2006.

B. G. Nordestgaard, M. J. Chapman, S. E. Humphries, H. N. Ginsberg, L. Masana et al., Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population : Guidance for Clinicians to Prevent Coronary Heart Disease : Consensus Statement of the European Atherosclerosis Society, European Heart Journal, vol.34, issue.45, pp.3478-3490, 2013.

, Familial Hypercholesterolemia Report of a second WHO Consultation, OMS, 1998.

L. Palacios, L. Grandoso, N. Cuevas, E. Olano-martín, A. Martinez et al., Molecular Characterization of Familial Hypercholesterolemia in Spain, Atherosclerosis, vol.221, issue.1, pp.137-142, 2012.

N. Patni, Z. Ahmad, and D. Wilson, Genetics and Dyslipidemia. Endotext, South, 2016.

T. R. Pedersen, Pleiotropic effects of statins : evidence against benefits beyond LDL-cholesterol lowering, Am J Cardiovasc Drugs, vol.1, pp.10-17, 2010.

M. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons et al., , p.2016, 2016.

, European Guidelines on cardiovascular disease prevention in clinical practiceThe Sixth Joint Task Force of the European Society of Cardiology and Other Societies on

, Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the R Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Heart Journal, vol.37, issue.29, pp.2315-2381

C. Pitsavos, I. Skoumas, D. Tousoulis, G. Metalinos, C. Masoura et al., The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia, Int J Cardiol, vol.134, issue.2, pp.280-281, 2009.

J. Plat and R. P. Mensik, Plant stanol and sterol esters int the control of bloddcholesterol levels : mechanism and safety aspects, Am J Cardiol, vol.96, issue.1A, pp.15-22, 2005.

M. C. Ray, Anti cholestérol : le traitement de l'hypercholestérolémie Publié le 18 novembre, 2016.

Z. Reiner, A. L. Catapano, D. Backer, G. Graham, I. Taskinen et al., ESC/EAS Guidelines for the management of the dyslipidaemias : the Task Force for the management of dyslipidaemias of the European Atherosclerosis Society (EAS), European Heart Journal, vol.32, issue.14, pp.1769-1818, 2011.

P. M. Ridker, A. Pradhan, J. G. Macfadyen, P. Libby, and R. J. Glynn, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention : An analysis from the JUPITER trial, Lancet, vol.380, issue.9841, pp.565-571, 2012.

B. M. Rifkind, Lipid Research Clinics Coronary Primary Prevention Trial : results and implications, Am J Cardiol, vol.54, issue.5, pp.30-34, 1984.
DOI : 10.1016/0002-9149(84)90854-3

E. Riquier, La levure de riz rouge, son impact sur le cholestérol et sa toxicité, Th D Pharm, 2011.

E. B. Rimm, P. Williams, K. Fosher, M. Criqui, and M. J. Stampfer, Moderate alcohol intake and lower risk of coronary heart disease : meta-analysis of effects on lipids and haemostatic factors, BMJ, pp.319-1523, 1999.

M. B. Roberfroid, V. Coxam, and N. Delzenne, Aliments fonctionnels. Editions Tec & Doc Lavoisier, 2008.

J. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc et al., Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, vol.372, issue.16, pp.1489-1499, 2015.

J. Robinson, B. S. Nedergaard, W. J. Rogers, J. Fialkow, J. M. Neutel et al., Effect of evolocumab or ezetimibe added to moderate or high intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia The LAPLACE 2 randomized clinical trial, The Journal of the American Medical Association, vol.311, issue.18, pp.1870-1882, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01256982

M. S. Sabatine, R. P. Giugliano, A. Keech, N. Honarpour, S. Wiviott et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, The New England Journal of Medicine, vol.376, issue.18, pp.1713-1722, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01896445

M. S. Sabatine, R. P. Giugliano, S. D. Wiviott, and F. J. Raal, Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events, N Engl J Med, vol.372, issue.16, pp.1500-1509, 2015.

B. Sablonnière, Biochimie & biologie moléculaire Omniscience, pp.321-327, 2006.

L. Sang-hak, Update on Familial Hypercholesterolemia : Diagnosis, Cardiovascular Risk, and Novel Therapeutics, Endocrinology and Metabolism, vol.32, issue.1, pp.36-40, 2017.

C. Sanofi-aventis, Monographie de produit incluant les renseignements pour les patients sur les médicaments Praluent® alirocumab

R. D. Santos, S. S. Gidding, R. A. Hegele, M. A. Cuchel, P. J. Barter et al., Defining severe familial hypercholesterolaemia and the implications for clinical management : a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel, The Lancet, vol.4, issue.10, pp.850-861, 2016.

N. Sattar, D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley et al., Statins and risk of incident diabetes : a collaborative meta-analysis of randomised statin trials, Lancet, vol.375, issue.9716, pp.735-742, 2010.

T. J. Schirris, G. H. Renkema, T. Ritschel, N. C. Voermans, A. Bilos et al., Statin-induced myopathy is associated with mitochondrial complex III inhibition, Cell Metab, vol.22, issue.3, pp.399-407, 2015.
DOI : 10.1016/j.cmet.2015.08.002

URL : https://doi.org/10.1016/j.cmet.2015.08.002

J. L. Schlienger, Nutrition clinique pratique, 2011.
DOI : 10.1016/s1957-2557(11)70228-0

P. Schuff-werner, S. Fenger, P. ;. Kohlschein, M. Futema, D. Nair et al., Genetic Architecture of Familial Hypercholesterolaemia, Current Cardiology Reports, vol.7, issue.5, p.44, 2012.

Z. M. Szczepiorkowski, N. Bandarenko, H. C. Kim, M. L. Linenberger, and M. B. Marques,

R. Sarode, Guidelines on the use of therapeutic apheresis in clinical practice : evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis, J Clin Apher, vol.22, issue.3, pp.106-175, 2007.

B. A. Taylor and P. D. Thompson, Statins and their effect on PCSK9-Impact and clinical relevance, Curr Atheroscler Rep, vol.18, issue.8, p.46, 2016.

J. Thiery and R. Burkhardt, PCSK9-"missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease, Herz, vol.41, issue.4, pp.281-289, 2016.

G. R. Thompson, Atherosclerosis, vol.LDL apheresis, issue.1, pp.1-13, 2003.

S. Tonstad, J. Knudtzon, M. Sivertsen, H. Refsum, and L. Ose, Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia, J. Pediatr, vol.129, issue.1, pp.42-49, 1996.

P. P. Toth and K. C. Maki, A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression), 2008.

, Should ezetimibe move to the 'Back of the Line' as a therapy for dyslipidemia ?, J Clin Lipidol, vol.2, issue.5, pp.313-317

R. Turgeon, A. Barry, and G. Pearson, Hypercholestérolémie familiale, Canadian Family Physician, vol.62, issue.1, pp.4-10, 2016.

G. Turpin, E. Bruckert, and M. Hypercholestérolémie, , 1999.

M. Vaubourdolle and . Biochimie, Hématologie Tome 2 Le Moniteur des pharmacies, 2013.

J. Versmissen, D. M. Oosterveer, M. Yazdanpanah, J. C. Defesche, D. C. Basart et al., Efficacy of statins in familial hypercholesterolaemia : a long term cohort study, BMJ, p.337, 2008.

V. Durand, D. Le-jeunne, and C. , Dorosz Guide pratique des médicaments, Maloine, 37 ème édition, 2018.

A. Vuorio, K. F. Docherty, S. E. Humphries, J. Kuoppala, and P. T. Kovanen, Statin treatment of children with familial hypercholesterolemia-trying to balance incomplete evidence of long-term safety and clinical accountability : are we approaching a consensus?, Atherosclerosis, vol.226, issue.2, pp.315-320, 2013.

D. S. Wald, J. P. Bestwick, and N. J. Wald, Child-parent screening for familial hypercholesterolaemia : screening strategy based on a meta-analysis, B Med J, vol.335, issue.7620, p.599, 2007.

A. Whitehead, E. J. Beck, and S. Tosh, Wolever TMS. Cholesterol-lowering effects of oat b-glucane : a meta-analysis of randomized controlled trials, Am J Clin Nutr, vol.100, issue.6, pp.1413-1421, 2014.

A. Wiegman, S. S. Gidding, G. F. Watts, M. J. Chapman, H. N. Ginsberg et al., Familial hypercholesterolemia in children and adolescents : gaining decades of life by optimizing detection and treatment, Eur Heart J, vol.36, issue.36, pp.2425-2437, 2015.

A. Wiegman, B. A. Hutten, E. De-groot, J. Rodenburg, H. D. Bakker et al., Efficacy and safety of statin therapy in children with familial hypercholesterolemia : a randomized controlled trial, JAMA, vol.292, issue.3, pp.331-337, 2004.

A. S. Wierzbicki and P. Grant, Drugs for hypercholesterolaemia-from statins to proprotein convertase subtilisin kexin 9 (PCSK9) inhibition, Clinical Medicine, vol.16, issue.4, pp.353-357, 2016.

D. Willians and J. Feely, Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors, Clin Pharmacokinet, vol.41, issue.5, pp.343-370, 2002.

J. L. Winters, Lipid apheresis, indications, and principles, J Clin Apheresis, vol.25, issue.2, pp.145-151, 2011.

L. Xiaobo, S. Racette, M. Lefevre, L. Ma, C. Spearie et al., Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism : A Randomized, Controlled Feeding Study in Humans, Circulation, vol.124, issue.5, pp.596-601, 2011.

E. Youngblom, M. Pariani, J. Knowles, . Hypercholesterolemia, and . Genereviews®, , 2014.

S. Yusuf, S. Hawken, S. Ôunpuu, T. Dans, A. Avezum et al., Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study) : Case-Control Study, The Lancet, vol.364, issue.9438, pp.937-952, 2004.

A. Zamora, L. Masana, M. Comas-cufí, A. Vila, N. Plana et al., , 2017.

, Familial Hypercholesterolemia in a European Mediterranean Population-Prevalence and Clinical Data from 2.5 Million Primary Care Patients, Journal of Clinical Lipidology, vol.11, issue.4, pp.1013-1022

Y. L. Zheng, F. Lian, Q. Shi, C. Zhang, Y. W. Chen et al., Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men : a systematic review and meta-analysis of prospective observational studies, vol.15, p.773, 2015.